Cycle Pharmaceuticals' HARLIKU™ (nitisinone) Tablets Receive First FDA-Approval as Treatment for Alkaptonuria (AKU)
Launching in July 2025, HARLIKU will be the first and only FDA-approved treatment for AKU, 1 an ultra-rare genetic metabolic disorder in which patients have a buildup of HGA that leads to osteoarthritis, ochronosis, and complications in the kidneys, and heart. 2 Patients with AKU often develop pain, reduced joint mobility, and require large joint replacements; the symptoms impede their physical functionality, emotional well-being, and quality of life. 2, 3
The approval of HARLIKU is based on data from a randomized, no-treatment controlled study of 40 patients with AKU. As part of the intramural research program of the National Human Genome Research Institute at the National Institutes of Health (NIH), Dr. Wendy J. Introne, MD and her team showed that nitisinone helped patients improve pain, energy levels, and physical functioning after three years of treatment, assessed using the 36-Item Short-Form Survey. 4
Steve Fuller, Chief Strategy Officer of Cycle Pharmaceuticals commented, "We are deeply grateful for Cycle's collaboration with Dr. Wendy Introne, Dr. Bill Gahl, and the broader team at the NIH, whose pioneering work laid the foundation for this FDA approval. We look forward to making HARLIKU available to U.S. AKU patients as soon as possible and remain committed to supporting the AKU community to the fullest extent of our capabilities."
'The approval of HARLIKU is an important advance for the AKU community. Our scientific team has translated decades of research into launching nitisinone as a new treatment option, and we stand hopeful that it can ease the significant burden of AKU,' said Dr. Wendy J. Introne, MD, of NIH's National Human Genome Research Institute (NHGRI).
Building on the company's previous success in rare diseases, HARLIKU will be Cycle Pharmaceuticals' eighth commercial product in the US.
Indications
HARLIKU™ is indicated for the reduction of urine homogentisic acid (HGA) in adult patients with alkaptonuria (AKU).
Important Safety Information
Do not prescribe HARLIKU to patients allergic to nitisinone or any other contained ingredients.
Warnings and Precautions:
Ocular Symptoms and Hyperkeratotic Plaques Due to Elevated Plasma Tyrosine Level:
Ocular signs and symptoms including keratitis, corneal opacities, corneal irritation, corneal ulcers, conjunctivitis, eye pain, and photophobia, have been reported in patients.
Perform slit-lamp examination prior to treatment and regularly thereafter. Reexamine patients if symptoms develop or tyrosine levels are > 500 micromole/L. Assess plasma tyrosine levels in patients with an abrupt change in neurological status.
Perform a clinical laboratory assessment, including plasma tyrosine levels, in patients with an abrupt change in neurological status.
Leukopenia and Severe Thrombocytopenia
In clinical trials, patients with hereditary tyrosinemia type 1 (HT-1) treated with another oral formulation of nitisinone and dietary restriction, developed reversible leukopenia, thrombocytopenia, or both. No patients developed infections or bleeding as a result of the episodes of leukopenia and thrombocytopenia. Monitor platelet and white blood cell counts during HARLIKU therapy.
Adverse Reactions:
The most common adverse reactions (≥1%) reported in patients with AKU taking nitisinone in clinical trials are elevated tyrosine levels, thrombocytopenia and keratitis.
Drug Interactions:
Nitisinone is a moderate CYP2C9 inhibitor and a weak CYP2E1 inducer. Potential clinical impact of Harliku administration with CYP2C9 substrates. Reduce the dosage of the co-administered drugs metabolized by CYP2C9 by half. Additional dosage adjustments may be needed.
Nitisinone is an inhibitor of OAT1/OAT3. Potential clinical impact of administration with OAT1/OAT3 substrates. Patients should be monitored for potential adverse reactions.
Use in Specific Populations:
Pregnancy: Limited available data with nitisinone use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
Lactation: The developmental and health benefits of breastfeeding should be considered against the mother's clinical need for HARLIKU, along with potential adverse effects on the breastfed infant from HARLIKU or from the underlying maternal condition.
Pediatric Use: The safety and effectiveness of HARLIKU have not been established in pediatric patients with AKU.
Geriatric Use: Insufficient data from clinical studies of HARLIKU to determine if patients ≥ 65 years of age respond differently. Elderly patients should be cautious reflecting any decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
For more detailed information, please refer to the full Prescribing Information at harliku.com/pi.
1-855-831-5413, or the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch.
US-HKU-2500032 | May 2025
References
HARLIKU (nitisinone) Tablets. Prescribing Information. Cycle Pharmaceuticals Ltd
Introne WJ, Perry M, Chen M. 2003 (updated 2021). Alkaptonuria. Available at: https://www.ncbi.nlm.nih.gov/sites/books/NBK1454/ [Accessed May 29, 2025]
Rudebeck M, Scott C, Sireau N, Ranganath L. 2020. A patient survey on the impact of alkaptonuria symptoms as perceived by the patients and their experiences of receiving diagnosis and care. JIMD Rep. 53(1):71-79. doi:10.1002/jmd2.12101
Spears KR, Rossignol F, Perry MB, et al. 2024 Patient-reported outcomes and functional assessments of patients with Alkaptonuria in a 3-year Nitisinone treatment trial. Mol Genet Metab. 143(1-2),108562. doi:10.1016/j.ymgme.2024.108562
©2025 Cycle Pharmaceuticals Limited. All rights reserved.
HARLIKU™ and Cycle Vita™ are trademarks of Cycle Pharmaceuticals Limited in the United States.
About Cycle Pharmaceuticals
Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering drug treatments and product support to the underserved rare disease community. Cycle Pharma focuses on rare genetic conditions in metabolic, immunology, urology, and oncology. In neurology, we focus on multiple sclerosis. Cycle Pharma is headquartered in Cambridge, UK and has offices in Boston, Massachusetts. For more information, please visit www.cyclepharma.com and follow us on X, LinkedIn and Facebook.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
a minute ago
- Axios
Potentially radioactive shrimp recalled at Walmarts in a dozen states
The Food and Drug Administration warned Tuesday against eating certain brands of shrimp because they might be, uh, radioactive. Why it matters: This is not your chance to develop amazing crustacean-based superpowers. Any prolonged exposure to radiation could cause sickness or even death. Driving the news: The FDA said Tuesday that certain types of Great Value raw frozen shrimp sold at Walmart may be contaminated with Cesium-137, a radioactive isotope. U.S. Customs and Border Protection initially told the FDA that Cesium-137 had been detected in containers at four different U.S. ports, the FDA said. The FDA then found the isotope in one sample of breaded shrimp. Indonesia's BMS Foods allegedly violated the Federal Food, Drug, and Cosmetic Act, the FDA said, because the product "appears to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137 and may pose a safety concern." Yes, but: No shrimp that tested positive for the radioactive isotope have entered the U.S. commerce supply, according to the FDA. All products from BMS are banned "from coming into the U.S. until the firm has resolved the conditions that gave rise to the appearance of the violation," the FDA said. Worth noting: The FDA oversees safety of both domestic and imported seafood. The agency seeks out any immediate or potential threats when assessing products for safety. Which Walmart shrimp products are radioactive? Zoom in: The FDA shared three Great Value products that should not be shared, eaten or served to others: Great Value brand frozen raw shrimp, lot code: 8005540-1, Best by Date: March 15, 2027 Great Value brand frozen raw shrimp, lot code: 8005538-1, Best by Date: March 15, 2027 Great Value brand frozen raw shrimp, lot code: 8005539-1, Best by Date: March 15, 2027 Context: These were sold at stores in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia, according to the FDA. Walmart told Axios in an email Tuesday that it recalled the product from impacted stores and customers who purchased the shrimp are eligible for a full refund. "The health and safety of our customers is always a top priority," Kelly Hellbusch, a Walmart spokesperson, said in a statement. "We have issued a sales restriction and removed this product from our impacted stores. We are working with the supplier to investigate." Symptoms of radiation from shrimp, Cesium-137 The FDA said the amount of Cesium-137 found in the shipment was low enough that it "would not pose an acute hazard to consumers." However, the warning "is a measure intended to reduce exposure to low-level radiation that could have health impacts with continued exposure over a long period of time," the FDA said. According to the Environmental Protection Agency, ingesting Cesium-137 can increase the risk of cancer. What to do with recalled Walmart shrimp
Atlantic
2 minutes ago
- Atlantic
The Future of Alzheimer's Diagnosis Is Now
A patient enters her general practitioner's office for a routine checkup. She is 65 years old, and—knock on wood—in good health: walking outside every morning, eating a thoughtful diet, and reading voraciously. All of this she naturally tells her doctor during the visit. However, lately she's been forgetting things here and there. Nothing major, she thinks. It's just a normal part of getting older. So this small detail she keeps to herself. But by holding on to that detail, the patient is also putting off a conversation that could change the course of her life as well as her family's. Memory change is not always a part of normal aging, with more than 7 million adults living with Alzheimer's disease in the United States—a number that is expected to almost double in the next few decades. The fear that talking about it will lead to a road of invasive procedures, life-changing diagnoses, and painful choices is all too common. However, new scientific developments in diagnostics have been made so medical experts can help diagnose or rule out Alzheimer's disease sooner, and more easily, than ever before with a simple blood test. In this new era, patients can rule out the disease as a diagnosis or talk to their doctors about care options and plan with their families if they receive a diagnosis. When patients receive a timely and accurate diagnosis, this opens up the opportunity for them to make plans for the future Brandy Matthews Vice President of Global and U.S. Medical Affairs for Eli Lilly and Company 'We have to overcome this barrier of stigma,' says Brandy Matthews, M.D., FAAN, vice president of global and U.S. medical affairs for Alzheimer's disease at Eli Lilly and Company, 'and then the reinforcement of the myths [so] that people will raise their hand when they begin to experience changes in their memory and thinking.' In addition to the laboratory developed tests that are already available and developed under the Clinical Laboratory Improvement Amendments (CLIA) to aid in Alzheimer's disease diagnosis, the FDA recently cleared the first in vitro diagnostic (IVD) blood biomarker test. These tests can be administered to symptomatic patients as part of a cognitive workup. 'The fact that there's been a recent FDA clearance for a blood biomarker in Alzheimer's disease is really critical and really big and I think will be a sort of a monumental shift in how we diagnose Alzheimer's disease,' says Anthony 'Nino' Sireci, M.D., MSc, senior vice president of clinical biomarkers, laboratories and diagnostics at Eli Lilly and Company. The work of developing new technology to diagnose a disease is painstaking and slow, but these breakthroughs are essential for patients. These advances not only offer hope to millions but also provide researchers like Matthews and Sireci with a profound sense of purpose. 'When patients receive a timely and accurate diagnosis, this opens up the opportunity for them to make plans for the future, to engage in lifestyle modifications, and to explore options for therapies that may target their symptoms or the underlying pathology of the disease,' says Matthews. Way back in 1906, the German neuropathologist Alois Alzheimer identified what he called 'an unusual disease of the cerebral cortex' marked by symptoms of memory loss. Using newly available technology, he identified two key pathological proteins in the neurons of his patients' brain cells: Beta-amyloid and tau. Beta-amyloid and tau are proteins produced naturally in the body. In patients with Alzheimer's disease, beta-amyloid starts to clump together, creating plaques between brain cells, while tau twists together into tangles inside brain cells. 'They are involved in a cascade of changes that happen in the brain, presumably initially with amyloid plaque accumulation, followed by tau tangle accumulation, leading to the dysfunction of the brain cells and then eventually neurodegeneration or shrinking of the brain. That results in the symptoms of Alzheimer's disease,' says Matthews. To be able to have a data-driven conversation, I think, is going to be pretty big in ensuring, number one, that patients are appropriately triaged Anthony 'Nino' Sireci, M.D. Senior Vice President of Diagnostics Development at Lilly Beta-amyloid plaques and tau tangles are the cause of the disease, but for nearly a century following their initial discovery, they could be identified only posthumously. This changed in 2002, when scientists identified amyloid plaque in the brain of a patient with a PET scan for the first time, using an imaging agent approved by the FDA in 2012. In 2022, the FDA cleared its first biomarker test measuring the presence of beta-amyloid in cerebrospinal fluid (CSF), drawn during a lumbar puncture (also known as a spinal tap). 'Modified fragments of those proteins are released into the cerebrospinal fluid,' says Sireci. 'And so those become some of the biomarkers that you measure in CSF.' While effective tools and necessary parts of the diagnostic process, PET scans and spinal taps are invasive and not always readily available, depending on where patients are located. This is where blood biomarkers come in, because beta-amyloid and tau aren't released only into CSF. 'Some of them actually leak out into the blood in super small quantities,' says Sireci. 'And that's what we use as the basis for identification of blood biomarkers in patients with Alzheimer's disease.' The traces found in these tests are smaller and harder to identify than the ones found in CSF. One challenge has been innovating over years to make blood test more closely resemble CSF – a major breakthrough developed over years of challenging work. And such tests require patients access and provider experience. In an ideal world, a simple blood sample could be collected at any doctor's office, even in rural or underserved communities, and sent to a major reference lab where, combined with the patient's initial cognitive assessment, it could provide information to help the treating physician to diagnose Alzheimer's disease without the need for additional confirmatory testing. That would vastly expand access to timely diagnosis. But there is still a lot of work to do between the clearance of a medical technology and its implementation. 'The obstacles now are not scientific,' says Sireci. 'Medicine is a logistical effort.' Are the [diagnostic] assay themselves robust enough that physicians feel confident in the results and confident in how they interpret them? That's really big. Anthony 'Nino' Sireci, M.D. Senior Vice President of Diagnostics Development at Lilly 'It's implementation,' he says. 'Are the [diagnostic] assay themselves robust enough that physicians feel confident in the results and confident in how they interpret them? That's really big.' But with any new diagnostic tools come questions. Are physicians educated in how to understand the results? Are they confident in those results? And once they are, are they actually able to order the test at scale from high quality labs? It's about quality and it's about access. And that's only on the medical side. What about patients? Will insurers reimburse the tests so that patients are not faced with high out-of-pocket costs? Will patients embrace them? Sireci is optimistic about both possibilities. A recent survey by the Alzheimer's Association found that 91 percent of patients would want a blood biomarker test if it were made available to them. A readily available blood biomarker test gives doctors and patients a tool to aid in accurate and timely diagnosis. That patient who walked into her general practitioner's office? She would undergo a routine cognitive exam (a recommended standard for all patients 65 and older). She would have an honest conversation with her doctor about changes she might be perceiving in her brain function, however slight. And if the doctor thought it was necessary, a referral to a specialist for a simple blood test would be administered to help inform next steps. Then, unlike in the decades when Alzheimer's disease could be diagnosed only symptomatically or after an invasive procedure, the doctor would lead her in an informed, fact-based discussion—right away. From that conversation, the patient could undergo a PET scan or CSF testing to confirm or rule out the diagnosis if necessary. 'To be able to have a data-driven conversation, I think, is going to be pretty big in ensuring, number one, that patients are appropriately triaged,' says Sireci, 'but also [that] they're not waiting years for a diagnosis, which unfortunately is what's happening today.' We're moving the needle for patients and giving physicians another very powerful tool to combat this disease. Anthony 'Nino' Sireci M.D., Senior Vice President of Diagnostics Development at Lilly This is crucial because Alzheimer's is a progressive disease. Timing is critical. The earlier a patient is diagnosed, the more time they have for planning, which could include treatment options a patient has available to them. They can set themselves up for counseling, talk to their families, and could choose to begin medical intervention. 'We've learned over time that initiating therapy in the earlier stages of disease can have greater impact,' says Matthews. 'And even within those early symptomatic stages of disease, there's evidence, across a class of medicines, that the earliest stages of early symptomatic Alzheimer's disease may demonstrate the greatest benefit of new therapies.' For Sireci, who has experience with Alzheimer's disease both as a doctor and as the family member of a patient, the most gratifying aspect of his research is knowing that it can help shorten what he calls the 'diagnostic odyssey.' 'Even if that just means getting the conversation to happen for the physician faster than it would've, then I'm happy,' says Sireci. 'That's a really big deal. We're moving the needle for patients and giving physicians another very powerful tool to combat this disease.' The Future of Alzheimer's Diagnosis Is Now Hear more from Brandy Matthews, Vice President of Global and U.S. Medical Affairs at Eli Lilly and Company, on the future of Alzheimer's diagnosis. learn more
Yahoo
an hour ago
- Yahoo
The FDA Is Warning People Not To Eat Possibly Radioactive Shrimp, And Everyone's Making Jokes About It
If you love eating shrimp, you might want to take a seat for what I'm about to tell you. ABC News reports that the FDA is warning the general American public not to eat, sell, or serve certain types of Great Value raw frozen shrimp sold at Walmart — because it may be radioactive. Yes, really. How did we get here? Well, according to an FDA press release, the shrimp in question "appears to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137 and may pose a safety concern." Cs-137, if you're not a dang chemist, is short for Cesium-137, a radioactive isotope. Related: If you want to know whether your shrimp is safe, you can head here to get all the details. But let's face it — you're here for the jokes people are making online, and there are more of them than there are shrimp in the sea: @pblest / Via @hedlike_a_hole / Via Related: @bungled_fiasco / Disney / Via @youwouldntpost / Via @MikeBeauvais / Via Related: @aintn0 / Fox / Via @SopranosWorld / Via @geeta_minocha / Via @_JiggityJohnson / Via Related: @_Yesternow_ / Via @DaveMcNamee3000 / Via @no_one__wins / Via Stay safe out there, shellfish fiends... Also in In the News: Also in In the News: Also in In the News:
